戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 nctive polymorphic ventricular tachycardia ('torsades de pointes').
2 ion of the QT interval and/or development of torsades de pointes).
3 ome with QT-related ventricular arrhythmias (torsades de pointes).
4 rs), can prolong the QT interval and provoke torsades de pointes.
5 enic afterdepolarizations thought to trigger torsades de pointes.
6 ciated with the potentially fatal arrhythmia torsades de pointes.
7 duced long QT interval syndrome (diLQTS) and torsades de pointes.
8  lead to interventions to reduce the risk of torsades de pointes.
9 sociated with the rare adverse drug reaction torsades de pointes.
10 adverse events including QT prolongation and torsades de pointes.
11 to hyperfunction of L-type channels, such as Torsades de Pointes.
12 quired and drug-induced long QT syndrome and torsades de pointes.
13 ation and is associated with case reports of torsades de pointes.
14 es, which are thought to trigger episodes of torsades de pointes.
15 f repolarization are not capable of inducing torsades de pointes.
16 ar tachycardia displaying characteristics of torsades de pointes.
17 nduce potentially lethal arrhythmia known as torsades de pointes.
18 ally the polymorphic ventricular tachycardia torsades de pointes.
19  predisposes to drug-induced QT prolongation/torsades de pointes.
20 ons in a cohort of consecutive patients with Torsades de Pointes; (3) the relationship between K(+) c
21                                              Torsades de pointes, a form of ventricular tachycardia,
22 ssociated with complex arrhythmias including torsades de pointes and 2 degrees atrioventricular block
23 ndrome, adult women carry a greater risk for Torsades de pointes and sudden cardiac death than do men
24              On the other hand, drug-induced torsades de pointes and symptomatic long QT syndrome hav
25 eads to polymorphic ventricular tachycardia (torsades de pointes) and sudden death.
26 ncope, polymorphous ventricular tachycardia (torsades de pointes), and sudden arrhythmic death.
27 ardiac events defined as syncope, documented torsades de pointes, and aborted cardiac arrest or sudde
28                    Cases of QT prolongation, torsades de pointes, and sudden death have been reported
29 el are associated with an increased risk for Torsades des Pointes arrhythmias and sudden death.
30 ontractions and fibrillations reminiscent of Torsades des Pointes arrhythmias, and they exhibit sever
31 se in the intracellular calcium may underlie torsades de pointes associated with intravenous tacrolim
32 that infrequently causes QT-prolongation and torsades de pointes cardiac arrhythmias.
33                          Consistently in the Torsades de Pointes cohort, concomitant acute infections
34 nd Europe with diLQTS, defined as documented torsades de pointes during treatment with a QT-prolongin
35 ated in causing QT interval prolongation and torsades de pointes, errors in the use of medications th
36 ars, and cases of prolonged QTc interval and torsades de pointes have been described in HIV-infected
37 eats after aftercontractions occurred before torsades de pointes in an in vivo dog model of drug-indu
38 s used to examine susceptibility to acquired torsades de pointes in chronic atrioventricular block an
39 voke the life-threatening cardiac arrhythmia torsades de pointes in some, but not all, individuals.
40 ing of noncardiac medications known to cause torsades de pointes, including fluoroquinolones and intr
41 ion of the QT interval and the occurrence of torsades de pointes is similar to more expensive alterna
42 c ventricular tachycardia, Brugada syndrome, torsades de pointes) may result in serious consequences,
43                                              Torsades de pointes occurred in 1 patient (0.1%) with CO
44 /31; 61%) versus WT (8/26; 31%; P<0.05), and Torsades de Pointes occurred more frequently (73% Cav3.1
45 nic atrioventricular block animals exhibited torsades de pointes on dofetilide, the arrhythmia was in
46 rhythmia was not VT storm, and no history of torsades de pointes or QT interval prolongation.
47 s system vasculitis and leukoencephalopathy, torsades de pointes, pulmonary vasculopathy, and pulmona
48 g class IC drugs, patients with low risk for torsades de pointes receiving selected class III agents,
49             Drug-induced QT prolongation and torsades de pointes remain significant and often unpredi
50 l prolongation in hospitalized patients with torsades de pointes risk factors.
51  some drug-induced arrhythmias, particularly torsades de pointes, risk factors are well defined.
52                                              Torsades de Pointes score was relatively high with ibuti
53                                  The risk of torsades de pointes should be assessed in patients who a
54 rhythmic agent with the propensity to induce torsades de pointes, substantially inhibits the current.
55                                              Torsades de pointes (TdP) +/-2 degrees atrioventricular
56 cteristic of long QT syndrome (LQTS) include torsades de pointes (TdP) and/or 2 degrees atrioventricu
57  healthy subjects and may be associated with torsades de pointes (TdP) arrhythmia, we tested the hypo
58 teria that are associated with initiation of torsades de pointes (TdP) in patients with acquired (a-)
59 oal of this study was to identify markers of torsades de pointes (TdP) in patients with drug-associat
60 e used for AF, excessive QT prolongation and torsades de pointes (TdP) often occur shortly after sinu
61 nse to hERG ion channel specific blocker was Torsades de Pointes (TdP) reentrant arrhythmia activatio
62 factors associated with azimilide-associated torsades de pointes (TdP) ventricular tachycardia.
63 eed for dose adjustment and the incidence of torsades de pointes (TdP) were identified.
64  a higher risk of lethal arrhythmias, called Torsades de pointes (TdP), compared to the opposite sex.
65 QT-prolonging medications with known risk of torsades de pointes (TdP), which is associated with high
66 oth syndromes can result in life-threatening torsades de pointes (TdP).
67 or for acquired long-QT syndrome (aLQTS) and torsades de pointes (TdP).
68  safety, including the risk of drug-induced 'torsades de pointes' (TdP) arrhythmia, is a major concer
69             Women have a higher incidence of torsades de pointes than men, but it is not known if the
70  QT-prolonging medications can predispose to torsades de pointes, there is a relative paucity of info
71 een shown to correlate with a higher risk of torsades de pointes, there is no established threshold b
72  it is not known if the risk of drug-induced torsades de pointes varies during the menstrual cycle.
73                       There were no cases of torsades de pointes, ventricular fibrillation, or polymo
74                  When a drug associated with torsades de pointes was prescribed to a patient at moder
75 ons occurred due to QTc prolongation, and no Torsades de Pointes was reported.